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Approximately 30% of elderly adults are cognitively unimpaired at time of death despite the presence of Alzheimer’s
disease neuropathology at autopsy. Studying individuals who are resilient to the cognitive consequences of
Alzheimer’s disease neuropathology may uncover novel therapeutic targets to treat Alzheimer’s disease. It is well established that there are sex differences in response to Alzheimer’s disease pathology, and growing evidence suggests
that genetic factors may contribute to these differences. Taken together, we sought to elucidate sex-speciﬁc genetic
drivers of resilience.
We extended our recent large scale genomic analysis of resilience in which we harmonized cognitive data across
four cohorts of cognitive ageing, in vivo amyloid PET across two cohorts, and autopsy measures of amyloid neuritic
plaque burden across two cohorts. These data were leveraged to build robust, continuous resilience phenotypes.
With these phenotypes, we performed sex-stratiﬁed [n (males) = 2093, n (females) = 2931] and sex-interaction
[n (both sexes) = 5024] genome-wide association studies (GWAS), gene and pathway-based tests, and genetic
correlation analyses to clarify the variants, genes and molecular pathways that relate to resilience in a sex-speciﬁc
manner.
Estimated among cognitively normal individuals of both sexes, resilience was 20–25% heritable, and when
estimated in either sex among cognitively normal individuals, resilience was 15–44% heritable. In our GWAS, we
identiﬁed a female-speciﬁc locus on chromosome 10 [rs827389, β (females) = 0.08, P (females) = 5.76 × 10−09, β
(males) = −0.01, P(males) = 0.70, β (interaction) = 0.09, P (interaction) = 1.01 × 10−04] in which the minor allele was
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associated with higher resilience scores among females. This locus is located within chromatin loops that interact
with promoters of genes involved in RNA processing, including GATA3. Finally, our genetic correlation analyses revealed shared genetic architecture between resilience phenotypes and other complex traits, including a femalespeciﬁc association with frontotemporal dementia and male-speciﬁc associations with heart rate variability traits.
We also observed opposing associations between sexes for multiple sclerosis, such that more resilient females had
a lower genetic susceptibility to multiple sclerosis, and more resilient males had a higher genetic susceptibility to
multiple sclerosis.
Overall, we identiﬁed sex differences in the genetic architecture of resilience, identiﬁed a female-speciﬁc resilience locus and highlighted numerous sex-speciﬁc molecular pathways that may underly resilience to
Alzheimer’s disease pathology. This study illustrates the need to conduct sex-aware genomic analyses to identify
novel targets that are unidentiﬁed in sex-agnostic models. Our ﬁndings support the theory that the most successful treatment for an individual with Alzheimer’s disease may be personalized based on their biological sex and
genetic context.
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Introduction
Alzheimer’s disease is a progressive, neurodegenerative disorder
leading to cognitive impairment. Alzheimer’s disease is marked by
two primary neuropathologies: amyloid plaques and neuroﬁbrillary
tangles. However, 30% of elderly adults are cognitively resilient to
the downstream consequences of Alzheimer’s disease pathology, as
they meet neuropathological criteria for Alzheimer’s disease at autopsy, yet remain cognitively unimpaired throughout life.1 Studying
resilient individuals may uncover quintessential information about
Alzheimer’s disease progression and enable the discovery of novel
therapeutic targets. In a recent study from our group2, we conducted
the largest genome-wide meta-analysis on cognitive resilience to
date and demonstrated a unique genetic architecture of cognitive
resilience that is distinct from that of Alzheimer’s disease.
Our original analysis did not investigate whether certain variants,
genes, or molecular pathways relate to cognitive resilience in a sexspeciﬁc manner. An emerging body of evidence suggests there are
sex differences in response to Alzheimer’s disease neuropathology.
There are notable sex differences in both Alzheimer’s disease neuropathology burden and the association between neuropathology burden and longitudinal cognitive decline. Speciﬁcally, a one-unit
increment in Alzheimer’s disease neuropathology at autopsy is associated with a 22-fold higher odds for clinical Alzheimer’s disease during life in females, but only a 3-fold higher odds in males.3,4 Similar sex
differences are also observed in biomarker studies of Alzheimer’s disease, such that females with more pronounced Alzheimer’s disease
neuropathology biomarkers show faster cognitive decline and faster
hippocampal atrophy than males with comparable levels of
Alzheimer’s disease biomarkers.5,6 Additionally, amyloid-positive females show both a faster rate of CSF tau7 and more pronounced tau accumulation in the medial temporal lobe as measured with tau PET6
compared to amyloid-positive males. Taken together, there is strong
evidence that the occurrence and downstream consequences of
Alzheimer’s disease neuropathology differ by biological sex.
In addition to the notable sex differences in Alzheimer’s disease biomarkers, there is similar evidence that sex-speciﬁc genetic factors contribute to sex differences in response to Alzheimer’s disease pathology.
The most robust genetic risk factor of late-onset Alzheimer’s disease,
the apolipoprotein E e4 (APOE e4) allele, has a stronger association
with clinical Alzheimer’s disease among females compared to males,
particularly between the ages of 55 and 70.8,9 Amyloid-positive females
with the APOE e4 allele have a faster rate of cognitive decline10,11 and
show higher tau burden compared to male counterparts.12 Beyond
APOE, work from our group has demonstrated sex-speciﬁc genomewide associations with CSF amyloid and tau levels,13 and autopsy measures of neuroﬁbrillary tangles,14 including a male-speciﬁc locus (e.g.
TSPAN13) that was recently replicated in the UK Biobank dataset.15

Together, these ﬁndings highlight the importance of including sexstratiﬁcation in genomic models to better understand the genetic architecture of Alzheimer’s disease.
To this end, we took a precision medicine approach to elucidate
sex differences in the genetic architecture of cognitive resilience to
Alzheimer’s disease pathology. We harmonized cognitive data
across four cohorts of cognitive ageing, leveraged a published model
of cognitive resilience that implements latent variable modeling,2,16
and performed a series of sex-aware genetic analyses. We hypothesized that genetic drivers of cognitive resilience differ between
males and females downstream of amyloidosis. By identifying sexspeciﬁc variants, candidate genes, and molecular pathways driving
cognitive resilience to Alzheimer’s disease pathology, the results of
this study will contribute to our understanding of Alzheimer’s disease progression in each biological sex and to the identiﬁcation of
novel therapeutic targets to treat Alzheimer’s disease.

Materials and methods
Participants
Our study included four cohorts of cognitive ageing [n (both sexes) =
5024, n (males) = 2093, n (females) = 2931]: Adult Changes in Thought
(ACT), Religious Orders Study and Rush Memory and Aging Project
(ROS/MAP), The Alzheimer’s Disease Neuroimaging Initiative
(ADNI) and Anti-Amyloid Treatment in Asymptomatic Alzheimer’s
Disease (A4). The A4 study began in 2014 as part of a clinical trial
and recruited cognitively unimpaired individuals.17 ADNI launched
in 2003 and is comprised of four phases of which ADNI1, ADNI2 and
ADNI-GO were included in this study. There are now over 1800 individuals aged 55–90 who have participated in ADNI and are comprised of a mix of individuals who are cognitively unimpaired and
individuals that have mild cognitive impairment, or Alzheimer’s
disease dementia (http://adni.loni.usc.edu/). ACT began in 1994, recruiting cognitively unimpaired individuals from the Seattle
area.18 ROS began in 1994 and recruited Catholic nuns, priests, and
brothers living in orders. MAP launched in 1997 and recruited cognitively unimpaired individuals from the Chicago area.19 Written informed consent was obtained from all participants, and research
was carried out in accordance with Institutional Review
Board-approved protocols. Secondary analyses of all data were approved by the Vanderbilt University Medical Center Institutional
Review Board.

Amyloid-PET acquisition
We leveraged in vivo amyloid PET data for two cohorts, ADNI and
A4. ADNI’s methods and protocols for their in vivo amyloid PET
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imaging can be found on their website, http://adni.loni.usc.edu/.
ADNI and A4 used a combination of GE, Philips, and Siemens technologies. Scans were conducted 50–70 min after tracer injection,
and acquired frames were 5 min in length. Both cohorts utilized
the 18F-ﬂorbetapir tracer, and a portion of ADNI’s study utilized
the 11C-Pittsburgh compound B (PiB) tracer instead. For each brain
region, standardized uptake value ratios (SUVRs) were calculated
and scaled using the cerebellum as the reference brain region. For
each participant, a SUVR composite score was calculated, comprised of cortical brain regions. For more extensive details regarding amyloid PET acquisition, see our recent paper.2

was calculated in each, including logical memory, Mini-Mental
State Exam along with Selective Reminding Test and digit symbol
in A4 and ADAS-Cog and Trail Making Test B in ADNI. As detailed
in the supplement of our ﬁrst publication with this phenotype,
the PACC behaves quite comparably in both ADNI and A4.2 The harmonized memory, executive function, and PACC composite scores
were extracted and leveraged in building resilience phenotypes. For
more extensive details regarding cognitive harmonization, see our
recent paper.2

Amyloid-PET harmonization

Cognitive resilience models were created using previously published protocols.2,16 Linear models were built in the combined autopsy dataset (ACT and ROS/MAP) and in the combined PET dataset
(ADNI and A4). Memory and executive function harmonized scores
were used as outcomes in the autopsy datasets covarying for age,
sex, and CERAD staging scores. In the PET datasets, memory and
PACC harmonized scores were used as outcomes, as well as harmonized executive function in ADNI, covarying for age, sex and harmonized amyloid PET SUVR. See Fig. 1A for an example of harmonized
memory scores by harmonized amyloid PET scores, by sex.
Standardized residuals from all linear models were extracted
and entered as indicators into latent variable models in Mplus (version 7.31).24 Two resilience models were built: residual cognitive resilience, with the standardized residuals as indicators, and a
second-order latent variable, combined resilience, which included
residual cognitive resilience and educational attainment as indicators (Fig. 1B). Inclusion criteria for the models required participants
to have cognitive scores for at least two of the cognitive domains.
Models were run in all individuals as well as in cognitively normal
individuals only. Factor scores were extracted from all models. For
average resilience scores by sex, see Table 1, and for more extensive
details regarding latent variable modelling, see our recent paper.2

As referenced in the above section, raw SUVR composite scores
(comprised of cortical brain regions) were obtained from ADNI
and A4. To normalize SUVR scores across cohorts and tracers, we
performed Gaussian mixture modelling (GMM) within each cohort
leveraging a previously published algorithm.20 Since ADNI scores
were a mix of PiB and ﬂorbetapir, we performed separate GMM
for each tracer within ADNI. Models were estimated among those
that were cognitively normal and then were subsequently applied
to all participants. Each GMM leveraged a two-component model
ﬁt, as this best ﬁt the bimodal property of the amyloid distribution.
The mean and the standard deviation of the amyloid negative distribution from each GMM was applied to standardize SUVR composites across all participants. The resulting harmonized SUVR
composite scores were on a z-score scale, representative of individual amyloid burden. Our group recently published a paper testing
different methods of amyloid PET harmonization, and more details
can be found in Raghavan et al.21 Overall, we concluded that there
are only minor differences between harmonization methods, and
the minor differences have less import with amyloid as a linear predictor in our models.2,21

Post-mortem assessment of neuropathology
Post-mortem assessments were conducted for participants in the
ACT and ROS/MAP cohorts. A well established measure of amyloid
plaque burden, the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) neuritic plaque staging scores, were
determined for each participant using standard protocols.17,18,22
CERAD scores were standardized between ACT and ROS/MAP,
such that higher CERAD scores were representative of higher individual amyloid burden in both cohorts. For more extensive details
regarding post-mortem assessment of neuropathology, see our recent paper.2

Cognitive harmonization
Cognitive data were harmonized across all cohorts using published,
modern psychometric techniques.23 Brieﬂy, qualiﬁed neuropsychologists/behavioural neurologists categorized test items into
memory or executive function domains (or neither). Overlapping
test items across cohorts were set as anchor items. Test items
were indicators in a conﬁrmatory factor analysis, with the scaled
anchor items allowing non-overlapping test items to be freely estimated. Memory was successfully harmonized across all four cohorts, as well as executive function across ACT, ROS/MAP and
ADNI. A4 did not have sufﬁcient anchor items for executive function harmonization, so a previously published composite, the
Preclinical Alzheimer Cognitive Composite (PACC) was leveraged
as an additional score across ADNI and A4. A four-item version

Latent variable modelling

Genotyping, quality control and imputation
Participants included in this study were genotyped using DNA extracted
from either brain or whole blood. Each cohort used the following genotype chips: A4 implemented the Illumina Global Screening Array and
ACT implemented the Illumina Human660W-Quad Array. ADNI implemented three chips: Human610-Quad, HumanOmniExpress, and Omni
2.5 M. Finally, ROS/MAP implemented three chips: Affymetrix Genechip
6.0, Illumina Human1 M, and Illumina Global Screening Array.
All genetic data were processed with a standardized quality control and imputation pipeline. Raw genetic data were ﬁltered to remove
variants with >5% sample missingness and minor allele frequency
(MAF) <1%. Then genetic data were ﬁltered to remove individuals
with >1% sample missingness, related individuals, and individuals
with mismatched sex. Additionally, X-chromosome genetic data
were compared between sexes, and variants with differential missingness (P < 1 × 10−07) were removed. Individuals who were
non-Hispanic white were retained for analysis. Those who selfreported as non-Hispanic white but were deemed to be genetic ancestry outliers in a principal component analysis (including the 1000
Genomes reference dataset) were subsequently removed (based on
a standard deviation ± ﬁve cut-point or by visual inspection).
Prior to imputation, variants were lifted over to genome build
38 (hg38). Then a Hardy-Weinberg equilibrium (HWE) exact test (P <
1 × 10−06) was performed in the whole sample for autosomal variants
and a HWE exact test (P < 1 × 10−06) was performed in the female sample only for X-chromosome variants and the male sample was
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Figure 1 Cognitive and biomarker data harmonization and cognitive resilience model. Memory, executive function, and Preclinical Alzheimer
Cognitive Composite (PACC) scores were harmonized across cohorts. Additionally, in vivo amyloid PET SUVRs were harmonized with Gaussian mixture
modelling. (A) Harmonized in vivo amyloid PET SUVR by harmonized memory scores are plotted by sex. (B) Linear models leveraging harmonized cognitive and amyloid data (harmonized in vivo PET or autopsy measures of amyloid plaque burden, CERAD scores) were residualized and fed as indicators
into a residual cognitive resilience latent variable model. The combined resilience latent variable model included educational attainment as an additional indicator.

ﬁltered accordingly. All variants were ﬁltered to remove palindromic
variants, same position variants, and variants with alleles mismatching with the reference panel. Genetic data were then imputed on the
Trans-Omics for Precision Medicine (TOPMed) program server.25–27
Post-imputation, genetic data were ﬁltered to remove variants with
an imputed R2 < 0.8 and duplicated/multi-allelic variants were
dropped. All genotyped variants were then dropped from the imputed data and the original genotypes were merged back in with
the rest of the imputed data, and then variants with a MAF <1%
were dropped. Finally, a HWE exact test (P < 1 × 10−06) was performed
on the imputed data in the whole sample for autosomal variants and
in the female sample only for X-chromosome variants and the male
sample was ﬁltered accordingly.
Genetic data requiring multiple datasets to be merged (ADNI, ACT and
ROS/MAP) were then checked for overlapping samples across genotype
chips. If sample overlap was present, the sample was dropped from the
chip with the lower coverage. Cleaned, imputed, genetic data from
each chip were compared and subsequently ﬁltered to remove variants
with mis-matching reference alleles and MAF differences of >10% and
then the genetic datasets across chips were merged. The merged datasets
were ﬁltered for cryptic relatedness. Genetic ancestry was assessed in the
merged dataset using a principal component analysis. Individuals who
self-reported as non-Hispanic white but were deemed to be genetic ancestry outliers (based on a standard deviation ± ﬁve cut-point or by visual
inspection) were subsequently removed.

Statistical analysis
Prior to performing genome-wide association studies (GWAS), cryptic relatedness across all four genetic datasets was assessed, removing 38 related individuals in total. In addition, for the combined ACT
and ROS/MAP dataset and for the combined ADNI and A4 dataset,
variants were ﬁltered for reference allele mismatches and MAF differences >10%. Then ACT and ROS/MAP were merged to result in a
combined autopsy dataset. Likewise, ADNI and A4 were merged to
result in a combined PET dataset. Combined genetic datasets were
subsequently used for all genetic analyses to facilitate joint analysis.

GWAS and genome-wide meta-analyses
GWAS were performed with PLINK linear association models
(v1.90b5.2, https://www.cog-genomics.org/plink/1.9).28 All GWAS

were run in the combined autopsy dataset and in the combined
PET dataset for all resilience phenotypes. Sex-stratiﬁed GWAS covaried for age and the ﬁrst three genetic principal components. The
sex-interaction GWAS also covaried for sex and included a single
nucleotide polymorphism (SNP) × sex interaction term. GWAS results were then meta-analysed across cohorts using a ﬁxed-effects
model with beta and standard error input (GWAMA v2.2.2).29 The
above models were also run identically in the sample restricted to
cognitively normal individuals, with the ﬁxed effects
meta-analyses implementing the minor allele frequencies calculated based on these individuals only. Additionally, an identical
GWAS and meta-analysis pipeline as described above was implemented with the X-chromosome genetic data. All meta-analysis results were restricted to SNPs present in both the autopsy and the
PET dataset, and these ﬁltered results were leveraged for all
post-GWAS steps discussed below.

SNP-heritability analysis
To determine the heritability of each resilience phenotype estimated in each sex and if estimates signiﬁcantly differed between
sexes, we performed a sex-aware heritability analysis that was outlined by Martin and colleagues.30,31 We ﬁrst leveraged the
Genome-Wide Complex Trait Analysis (GCTA) software tool to calculate genetic relatedness matrices in all individuals, in males only,
and in females only. Then we implemented the GCTA restricted
maximum likelihood statistical method with the genetic relatedness matrices to calculate SNP-based heritability estimates in all
individuals, in males only, and in females only.32 Next, we performed a test to determine if the heritability estimates for each resilience phenotype signiﬁcantly differed between sexes. To
perform this test, we calculated z-scores with the following formula: z-score = (h2females−h2males)/√[h2females(SE)2 + h2males(SE)2].
Then, we obtained P-values for each z-score from the normal distribution based on a one-tailed test.

Variant annotation
Functional annotation was performed with Functional Mapping
and Annotation (FUMA, v1.3.6a)33 on genome-wide signiﬁcant loci
from the meta-analyses. All variants in linkage disequilibrium
with top variants were also considered in annotation. In brief,
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Table 1 Cohort demographics by sex

Age, years
Educationa, years
Residual Cognitive Resilience Score
Combined Resilience Scorea
Amyloid statusa
Alzheimer’s disease diagnosisa
APOE e4 carrier status

Males (n = 2093)

Females (n = 2931)

Both sexes (n = 5024)

76.70 ± 8.80
17.01 ± 3.07
0.06 ± 0.89
0.08 ± 0.42
857 (40.95%)
236 (11.28%)
659 (31.49%)

76.84 ± 10.26
16.05 ± 2.84
0.06 ± 0.87
−0.02 ± 0.39
1287 (43.91%)
381 (13.00%)
898 (30.64%)

76.78 ± 9.68
16.45 ± 2.98
0.06 ± 0.88
0.02 ± 0.40
2144 (42.68%)
617 (12.28%)
1557 (30.99%)

Categorial values given in n (%); continuous values given in mean ± standard deviation.
a

Signiﬁcant difference between sexes via a t-test (continuous variables) or via a chi-square test (categorical variables).

FUMA performs three types of mapping: expression quantitative
trait locus (eQTL), Hi-C 3D chromatin interaction, and positional.
Speciﬁcally, FUMA compiles chromosome conformation capture
with high throughput sequencing (Hi-C) data from multiple databases. Hi-C is an assay that looks for enrichment of DNA sequences
associated with chromatin loops at different locations in the genome. FUMA also looks to see if these enriched regions overlap
with gene promotor or enhancer sequences. All types of mapping
are performed in a tissue and a cell-type speciﬁc manner.34

Alzheimer’s disease risk loci analysis
We compiled Alzheimer’s disease risk variants from three well-known,
published Alzheimer’s disease genome-wide meta-analyses.35–37
Leveraging our meta-analysis results, we looked at each risk variant’s
association with residual cognitive resilience and with combined resilience in males, in females, and in the sex-interaction models.

Gene and pathway-based tests
Gene and pathway-level tests were performed with Multi-marker
Analysis of GenoMic Annotation (MAGMA v1.09—the version of
MAGMA with the known P-value inﬂation bug ﬁxed)38 on all
meta-analysis results. First, permutation-like gene tests were performed to determine if a higher number of signiﬁcant variant-level
P-values existed in a predeﬁned gene window than expected by
chance. This process was conducted across the entire genome. All
gene-level results were then entered into permutation-like pathway tests to determine if there were more signiﬁcant gene test
P-values associated with known biological pathways than expected
by chance. We leveraged two sets of curated pathway annotations
from the Molecular Signatures Database (MSigDB) v.7.0 (downloaded on 5 February 2020), the curated gene set (C2) and the ontology gene set (C5).39 In total, we tested 18 243 genes and 12 173
biological pathways. All gene and pathway tests were adjusted for
multiple comparisons using the false discovery rate (FDR) procedure, and an a priori signiﬁcance threshold was set at PFDR < 0.05.

Genetic correlation analyses
Genetic correlation tests were performed between our resilience
meta-analysis summary statistics and GWAS summary statistics
of 65 complex traits using the Genetic Covariance Analyzer
(GNOVA).40 To calculate genetic covariances with GNOVA, z-scores
were quantiﬁed from each variant-level association in each set of
GWAS summary statistics. Linkage disequilibrium scores were
also quantiﬁed from an ancestry-matched reference panel (e.g.
1000 Genomes European reference panel). Then genetic covariances between trait pairs were calculated with the z-scores mentioned above. Inﬂation due to linkage disequilibrium structure

was adjusted by implementing the ancestry-matched genomewide linkage disequilibrium scores. Genetic covariances were also
adjusted for sample overlap (between GWASs). For all genetic correlation analyses, we implemented GNOVA’s simplest, no annotation model. After conducting the genetic correlation analyses,
genetic covariances were adjusted for multiple comparisons using
the FDR procedure, and an a priori signiﬁcance threshold was set at
FDR < 0.05.

APOE × sex sensitivity analysis
A set of linear regressions were performed in R (v.4.0.3) with our resilience phenotypes as the outcomes, age and the ﬁrst three genetic
principal components as covariates, and inclusion of an APOE genotype × sex interaction term. APOE genotype was ﬁrst coded with an
APOE e4 additive model and then in subsequent analyses with an
APOE e2 dominant model. An e2 dominant model was implemented
due to sample size constraints of homozygous e2 individuals. All
linear regressions were performed in the combined autopsy dataset
and in the combined PET dataset and then meta-analysed across
cohorts (R metafor package).41

Data availability
Data from the ADNI and A4 studies are shared through the LONI Image
and Data Archive (https://ida.loni.usc.edu/). Data from ROS/MAP can be
requested at www.radc.rush.edu. Data from ACT can be accessed
through the Data Query Tool (http://act.kpwashingtonresearch.org/
dqt/). GWAS summary statistics will be available through NIAGADS
(https://www.niagads.org/datasets/).

Results
Cohort demographics stratiﬁed by sex are presented in Table 1.
T-tests were performed between sexes for age, education, residual
cognitive resilience score, and combined resilience score.
Education and combined resilience score signiﬁcantly differed between sexes based on P-values from the t-tests, whereby education
and combined resilience were higher in males compared to females. Age and residual cognitive resilience score did not signiﬁcantly differ between sexes. Chi-square tests were performed
between sexes for amyloid status, Alzheimer’s disease diagnosis,
and APOE e4 carrier status. Amyloid status and Alzheimer’s disease
diagnosis signiﬁcantly differed between sexes based on P-values
from chi-square tests, whereby amyloid status and Alzheimer’s
disease diagnosis were both higher in females compared to males.
APOE e4 carrier status did not signiﬁcantly differ between sexes.

Sex-speciﬁc genetics of resilience

SNP-heritability results
We calculated SNP-heritability estimates among the entire sample
and among cognitively normal individuals, using the GCTA restricted maximum likelihood method.32 All results are presented
in Table 2, but we will discuss the results among cognitively normal
individuals which were statistically signiﬁcant. Estimated among
cognitively normal individuals of both sexes, resilience was 20–
25% heritable. Estimates among male cognitively normal individuals were 26–44%, whereas among female cognitively normal individuals, estimates were 15–27%. We next tested to see if these
heritability estimates signiﬁcantly differed between sexes by calculating z-scores and generating P-values from the normal distribution from a one-tailed test. Heritability estimates did not
signiﬁcantly differ between sex for any of our phenotypes.
Additionally, SNP-heritability estimates were attenuated when estimated among the whole sample but remained nominally signiﬁcant when estimated among males and females combined and
among males only.

Variant-level results
Variant-level results are presented in Supplementary Tables 1–12.
QQ plots for all genome-wide meta-analyses with estimates of genomic lambda are presented in Supplementary Figs 1–3. For our residual cognitive resilience phenotype, we did not identify any
sex-speciﬁc genome-wide signiﬁcant loci in all participants or
among cognitively normal individuals. For our combined resilience
phenotype, we identiﬁed a genome-wide signiﬁcant femalespeciﬁc locus on chromosome 10 [rs827389, β(females) = 0.08,
P(females) = 5.76 × 10−09, β(males) = −0.01, P(males) = 0.70, β(interaction) = 0.09, P(interaction) = 1.01 × 10−04] among cognitively normal individuals (Fig. 2) whereby the minor allele was associated
with higher resilience scores. Although this locus was not genomewide signiﬁcant in residual cognitive resilience, the direction of effect was the same and the locus fell just below the genome-wide
signiﬁcance threshold in females [β(females) = 0.16, P(females) =
3.65 × 10−07]. No signiﬁcant sex-speciﬁc associations were observed
for combined resilience in all participants. We conducted
APOE-by-sex sensitivity analyses on all resilience phenotypes. No
associations were statistically signiﬁcant (Supplementary
Table 13).
Functional annotation was performed on the genome-wide signiﬁcant female chromosome 10 resilience locus (among cognitively
normal individuals). All variants in linkage disequilibrium with
rs827389 (top variant) were considered in annotation. The female
locus was signiﬁcantly enriched in Hi-C chromatin loops in multiple tissues, including foetal and adult cortex, aorta, left/right ventricle, liver, spleen, mesendoderm, mesenchymal stem cells, and
trophoblast-like cells (Supplementary Table 14). Furthermore, enriched chromatin loops overlapped with promoter regions for multiple genes involved in RNA processing (Supplementary Table 15),
including GATA3.

Alzheimer’s disease risk loci analysis
Sex-stratiﬁed and sex-interaction resilience associations with
known Alzheimer’s disease genetic loci are presented in
Supplementary Tables 16 and 17. In our residual cognitive resilience analysis, we observed eight nominally signiﬁcant sex-interactions at three Alzheimer’s disease loci, whereby associations were
male-speciﬁc for two loci, MS4A6A and PTK2B. Among males, the
MS4A6A locus was positively associated with resilience and the
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PTK2B locus was negatively associated with resilience.
Additionally, PICALM showed a ﬂipped effect between sexes,
whereby it was negatively associated in males and positively associated in females. Similarly, in our combined resilience analysis, we
observed nine nominally signiﬁcant sex-interactions at six
Alzheimer’s disease loci, whereby associations were male-speciﬁc
for four loci, MS4A6A, PTK2B, KAT8, and SORL1. Among males, the
KAT8 and PTK2B loci were negatively associated with resilience,
whereas the MS4A6A and SORL1 loci were positively associated
with resilience.

Gene and pathway-level results
Gene test results are presented in Supplementary Tables 18–21 and
pathway test results are presented in Supplementary Tables 22–25.
We did not observe any genes or pathways that survived adjustment for multiple comparisons (FDR < 0.05) for any of the resilience
phenotypes. However, we did observe one gene test for combined
resilience that was close to surviving adjustment for multiple comparisons among females, and that gene was LEAP2 on chromosome
5 [PFDR(females) = 0.0998, PFDR(males) = 0.9971].

Genetic correlation results
We performed sex-stratiﬁed and sex-interaction genetic correlation analyses between our resilience phenotypes and 65 complex
traits (Supplementary Tables 26–30). In this section, we will be presenting the male and female results, leveraging the sex-interaction
results to aid in interpretation. For the entirety of the male, female
and sex-interaction genetic correlation analysis results, see
Supplementary Tables 26–30.
In our residual cognitive resilience phenotype, associations
with 11 traits in males and six traits in females survived adjustment
for multiple comparisons (FDR < 0.05) among all participants. For
residual cognitive resilience among cognitively normal participants, 13 traits in males and nine traits in females survived adjustment for multiple comparisons (FDR < 0.05). In our combined
resilience phenotype, associations with 22 traits in males and seven traits in females survived adjustment for multiple comparisons
(FDR < 0.05) among all participants. For combined resilience among
cognitively normal participants, 20 traits in males and 12 traits in
females survived adjustment for multiple comparisons (FDR < 0.05).
Of the traits that survived adjustment for multiple comparisons
in at least one sex for residual cognitive resilience, one trait displayed a signiﬁcant sex-interaction effect. This trait was frontotemporal dementia (FTD, Fig. 3A), and it was negatively associated in
females, but was not associated in males. Of the traits that survived
adjustment for multiple comparisons in at least one sex for residual
cognitive resilience among cognitively normal individuals, three
traits displayed a signiﬁcant sex-interaction effect. These traits included asthma, cannabis dependence, and multiple sclerosis,
whereby asthma and multiple sclerosis were negatively associated
in females and cannabis dependence was positively associated in
females, and none of the three traits were associated in males.
Of the traits that survived adjustment for multiple comparisons
in at least one sex for combined resilience, six traits displayed a signiﬁcant sex-interaction effect. These included Coeliac disease
(Fig. 3B), SDNN (resting heart rate SD of NN intervals), resting heart
rate pvRSA/HF (peak-valley respiratory sinus arrhythmia or high frequency power) and resting heart rate RMSSD (root mean square of
successive differences) (Fig. 3B), which were positively associated
in males and not associated in females, as well as inﬂammatory
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Table 2 SNP-heritability estimates by sex
Both sexes

h2
Residual Cognitive Resilience
4.16%
Residual Cognitive Resilience (CN) 20.90%
Combined Resilience
19.71%
Combined Resilience (CN)
25.25%

h2(SE) P-value
4.75%
5.48%
8.89%
7.95%

Males

h2

h2(SE)

Females

P-value

h2

h2(SE)

Sex differences
test
P-value

0.11
7.65%
9.09% 0.10
5.61%
10.60% 0.31
9.86% 1.24 × 10−4
6.80 × 10−11 25.82% 11.60% 5.07 × 10−5 27.17%
0.01
29.42% 19.48% 0.03
0.0001% 14.50% 0.50
12.37% 0.06
2.33 × 10−7 44.11% 18.64% 9.57 × 10−5 14.93%

Z-score P-value
−0.15
0.09
−1.21
−1.30

0.88
0.93
0.23
0.19

CN = cognitively normal. h2 values are the V(G)/Vp estimates calculated from the GCTA restricted maximum likelihood statistical method (with genetic relatedness matrices).
Sex differences test P-values were generated from the normal distribution based on a one-tailed test.

Figure 2 Minor allele of female-speciﬁc genome-wide signiﬁcant locus on chromosome 10 (with rs827389) associated with higher combined resilience
scores among cognitively normal females. (A) Miami plot with female variant associations on the top in pink and male variant associations on the bottom in blue. (B) Forest plot of rs827389 by cohort and by sex, including ﬁxed-effects meta-analysis estimates. (C) Locus Zoom plots displaying the genomic region surrounding the chromosome 10 locus, by sex.

bowel disease and sleep duration, which were negatively associated
in males and were not associated in females. In addition, multiple
sclerosis had opposing effects between sexes (Fig. 3B) such that it
was negatively associated in females and positively associated in
males. Of the traits that survived adjustment for multiple comparisons in at least one sex for combined resilience among cognitively
normal individuals, seven traits displayed a signiﬁcant sexinteraction effect. Internalizing problems was positively associated
in females and not associated in males. Body mass index was negatively associated in males and not associated in females. Resting
heart rate pvRSA/HF and resting heart rate RMSSD were positively

associated in males and not associated in females. Multiple sclerosis
and asthma had opposing effects between sexes such that both
traits were positively associated in males and negatively associated
in females.

Discussion
We performed a series of sex-aware genetic analyses on cognitive
resilience phenotypes to characterize sex-speciﬁc variant, gene
and pathway-level effects contributing to cognitive resilience to
Alzheimer’s disease neuropathology. We identiﬁed a novel female-

Sex-speciﬁc genetics of resilience

BRAIN 2022: 145; 2541–2554

| 2549

Figure 3 Sex-speciﬁc shared genetic architecture between resilience and complex traits. Genetic covariance estimates with 95% conﬁdence intervals
are shown in the ﬁgure, with female estimates in pink and male estimates in blue. Grey conﬁdence intervals denote a non-signiﬁcant covariance estimate irrespective of sex. (A) Genetic covariance estimates with residual cognitive resilience, by sex, for Alzheimer’s disease and for FTD. (B) Genetic
covariance estimates with combined resilience, by sex, for three HRV traits and for two autoimmune traits.

speciﬁc locus on chromosome 10, and we highlighted a number of
high-quality female-speciﬁc candidate genes implicated in RNA
processing linked to the top variant in the region. Finally, we characterized a number of novel sex-speciﬁc genetic covariances between cognitive resilience and relevant traits, including a
female-speciﬁc association with frontotemporal dementia, malespeciﬁc associations with inﬂammatory bowel disease, sleep duration, body mass index and HRV traits, and opposing associations
between sexes for asthma and multiple sclerosis. Overall, our results highlight the value of incorporating sex-stratiﬁed analyses
into genetic studies of Alzheimer’s disease and suggest that
female-speciﬁc genetic drivers of resilience may lie along
immune-related pathways, while male-speciﬁc genetic drivers
may fall along cardiovascular-related pathways.

Cognitive resilience is a highly heritable trait in both
sexes
As we reported previously, the heritability estimates of resilience
traits are slightly higher when restricting the sample to cognitively
normal individuals,2 perhaps due to an increase in phenotypic heterogeneity when including individuals with dementia, and indeed
we observed a similar pattern in the present heritability analyses
when stratifying by sex. Speciﬁcally, in both male-stratiﬁed and
female-stratiﬁed analyses, we observed higher heritability estimates
that reached statistical signiﬁcance among normal cognition
participants (Table 2) and lower heritability estimates when including individuals with dementia (Table 2). While we did note slightly
higher heritability estimates for males compared to females (Table
2), particularly for the combined resilience trait, the difference between sexes did not reach statistical signiﬁcance. As sample sizes expand in future analyses, it will be interesting to see whether sex

differences in heritability do emerge, but at present we can only conclude that these resilience traits appear to be heritable in a similar
manner across sexes.

Sex-speciﬁc shared genetic architecture between
cognitive resilience and autoimmune disorders
We observed sex-speciﬁc genetic covariances between resilience
and autoimmune traits (Fig. 3B and Supplementary Tables 26–29),
whereby genetic predisposition towards resilience was associated
with reduced genetic risk for autoimmune traits among females
(e.g. lupus, multiple sclerosis) and increased genetic risk for autoimmune traits among males (e.g. lupus, multiple sclerosis,
Coeliac disease). It is notable that there are well-documented sex
differences in trait prevalence for autoimmune disorders, with
much higher trait prevalence in females compared to males.42,43
Alzheimer’s disease has known immune dysregulations and shares
biology with autoimmune disorders, such as the imbalance of Th1
pro-inﬂammatory and Th2 anti-inﬂammatory cytokines in both
Alzheimer’s disease and multiple sclerosis.42,43 Thus, it is perhaps
intuitive that genetic factors that predispose lower susceptibility
to autoimmune diseases are related to resilience among females.
In contrast, it is unclear why males would show an inverse association with higher genetic susceptibility to autoimmune conditions
relating to more genetic resilience to Alzheimer’s disease.
A sex difference in the genetic architecture of cognitive resilience could be due to differences in sex hormones, sex chromosomes or both. Sex hormones may modulate sex differences in
the genetic aetiology of autoimmune disorders and resilience.
Reproductive years account for the largest sex differences in autoimmune trait prevalence,42,43 and loss of oestrogen has a well established relationship with cognitive decline.44–46 In addition, males lose
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their sex hormones later in life than females, coinciding with when
males tend to be diagnosed with autoimmune disorders.42,43
X-chromosome effects are another possible explanation, given the
role of X-inactivation and X-chromosome instability in both autoimmunity and cognition.47–49 Recently, a second X chromosome
was shown to promote survival in ageing50 and harbour resilience51
against Alzheimer’s disease in an ageing mouse model (irrespective
of clinical Alzheimer’s disease risk), further supporting the possibility
of X-chromosome effects as a mechanism underlying both autoimmunity and resilience. However, in contrast, mouse models of
multiple sclerosis and lupus have shown that a second sex chromosome confers increased susceptibility.52,53 Additionally, having two X
genes is aligned with more susceptibility to lupus in humans.54,55
Thus, it is unclear at this point whether X-chromosome effects could
possibly be driving the resilience and autoimmunity sex difference
we observed. A third possibility is that differences in metabolic processes between males and females explain genetic sex differences in
autoimmunity and resilience. Age-related metabolic shifts tend to be
coupled with increased neuroinﬂammation in females, whereas
metabolic shifts do not show this same coupling in males.56,57
Regardless of the mechanism, our results suggest dramatic sex differences in the cognitive consequences of polygenic protection
against autoimmune traits that deserve future attention.

Male-speciﬁc shared genetic architecture between
cognitive resilience and cardiovascular traits
We observed male-speciﬁc positive genetic covariances with three
heart rate variability traits, such that more resilient males had a
higher genetic susceptibility to more favourable heart rate variability (Fig. 3B). It is well established that higher HRV is a marker of good
heart health and that HRV decreases with ageing.58–60 The association between the genetic architecture of HRV and the genetic
architecture of resilience could be due to (i) HRV driving more resilience in males; (ii) reverse causality with genetic factors that predispose towards cognitive resilience driving better HRV in males; or
(iii) common genetic factors drive both HRV and resilience through
independent pathways (i.e. pleiotropy). In support of a causal connection, evidence suggests that lower degrees of HRV are associated with cognitive impairment61,62 and that age-related HRV
differences are sex dependent. Young, healthy females have a lower HRV compared to males, but with advanced age this sex difference is no longer apparent. In fact, elderly males tend to have
lower HRV than elderly females,59 perhaps due to a survival bias4
from male susceptibility to midlife cardiovascular events.63 In support of reverse causality, resilience to both cognitive and HRV decline may work through similar circuitry, with prefrontal cortical
brain circuitry as an example of this possible shared circuitry that
could potentially drive better HRV.58,61 Multiple groups have shown
a link between prefrontal cortical brain activity and HRV, with more
than one group pointing towards HRV as a possible early marker of
cognitive decline.58,61 While the possibility of better HRV driving resilience is exciting with some supporting evidence in the literature,
future work must investigate each of these scenarios in great detail
to determine causality.

Female-speciﬁc shared genetic architecture between
cognitive resilience and FTD
We observed a signiﬁcant negative genetic covariance in females
between FTD and residual cognitive resilience (Fig. 3A), suggesting
more resilient females are less genetically susceptible to FTD.

J. M. Eissman et al.
Notably, the genetic covariance between resilience and
Alzheimer’s disease was not signiﬁcant in either sex (Fig. 3A).
Illán-Gala and colleagues64 conducted a sex-aware analysis on behavioural variant FTD (bvFTD), the most common form of FTD,
and observed that females had more cognitive reserve in FTD compared to males. Leveraging a residual approach similar to our
study’s models, this group observed that females had
better-than-expected executive function scores and less behavioural changes given pathology burden compared to males.64
Importantly, females had a higher amount of atrophy than males
at FTD diagnosis, yet had similar disease progression.64 As mentioned previously, a recent study in ageing mouse models demonstrated that a second X chromosome promotes survival in
ageing50 and resilience to Alzheimer’s disease51 irrespective of clinical Alzheimer’s disease risk. Taken together, this evidence from
the literature and our FTD and Alzheimer’s disease genetic covariance ﬁndings all suggest that it may be the case that there is sexspeciﬁc shared genetic architecture of reserve/resilience across dementias subtypes, which contributes to disease protection agnostic
to the underlying neuropathology.
However, Illán-Gala et al.64 also points out that Alzheimer’s disease is a posterior brain disease, with the anterior cingulum serving
as a region of resilience in Alzheimer’s disease, whereas bvFTD is
more of an anterior brain disease. Thus, possibly bvFTD sex-speciﬁc
cognitive reserve/resilience brain regions are not the same as
Alzheimer’s disease sex-speciﬁc cognitive reserve/resilience brain
regions.64 Therefore, it may alternatively be the case that sexspeciﬁc reserve/resilience brain regions across dementia subtypes
differ, but sex-speciﬁc genetic factors driving reserve/resilience
are shared across subtypes and harbour some protection from the
downstream consequences of neuropathology agnostic to dementia subtype. Perhaps, it could also be the case that we are observing
an indirect effect between FTD and resilience, such that similar
genetic architecture is independently contributing to both disorders.
More sex-aware studies on the genetic architecture of reserve/
resilience to different dementia subtypes will need to be conducted
to determine causality.

Female-speciﬁc candidate genes implicated in RNA
processing
Functional annotation of the chromosome 10 genome-wide signiﬁcant locus (with rs827389) in cognitively normal females (Fig. 2) suggests its possible regulatory effects. This locus was signiﬁcantly
enriched in Hi-C chromatin loops at multiple gene promoters of
genes implicated in RNA processing. These genes included: KIN, a
DNA/RNA binding protein, TAF3, a TATA-box binding protein, and
GATA3, a zinc-ﬁnger transcription factor (Supplementary Table 15).
It is notable that a promising female-speciﬁc candidate gene we identiﬁed through functional annotation is GATA3, which encodes a ‘pioneer transcription factor’ that can bind heterochromatin and
recruit factors to change chromatin state.65 GATA3 is involved in sonic hedgehog signalling, a quintessential signalling pathway for pattern formation in neuronal development.66 It is also involved in
embryonic development, inﬂuencing genes involved in extracellular
matrix formation.67
In addition to involvement with neuronal development, GATA3
also controls immune T-cell fate.65 Speciﬁcally, GATA3 controls
CD4+ effector cells: Th2 cells. CD4+ effector cells can produce autoantibodies against amyloid and therefore harbour protection
against amyloid burden.68 It is thought that genetic drivers of
immune-cell proﬁles may in part explain sex differences observed
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in response to Alzheimer’s disease pathology.69,70 Thus, it is noteworthy to see an immune-target arise at both the variant-level
with GATA3, and at the whole genome level with our genetic correlation analyses. Taken together, this evidence points towards
GATA3 as a female-speciﬁc candidate gene, and overall alludes to
the idea that female resilience to Alzheimer’s disease pathology
may involve regulation of RNA processing, although future studies
need to replicate and to further elucidate this ﬁnding.

residual cognitive resilience phenotype. However, it is notable
that genetic covariances for more traits were signiﬁcant in at least
one sex for combined resilience compared to residual cognitive resilience. Overall, we are gaining additional power by leveraging a
second-order latent variable, combined resilience, in genetic analyses due to the contributions of educational attainment in conferring resilience. We believe this framework should be integrated into
future analyses.

Alzheimer’s disease genetic loci associations with
cognitive resilience trend towards male-speciﬁc
effects

Strengths and limitations

As shown in Supplementary Tables 16 and 17, we observed nominally signiﬁcant sex-speciﬁc associations with resilience at wellknown Alzheimer’s disease loci.35–37 These associations were malespeciﬁc at MS4A6A, PTK2B, KAT8 and SORL1, and a ﬂipped effect between sexes was observed at the PICALM locus. Multiple groups
have shown that SORL1 may exhibit sex-speciﬁcity, including evidence showing SORL1 variants to be detrimental in females.71–73
This aligns with what we observed in our study, as we saw a negative association with resilience at a SORL1 variant in females but a
positive association in males. In addition, prior evidence suggests
sex-speciﬁcity at the PICALM locus. A recent study of cognitively
unimpaired individuals demonstrated a negative association in
males as well as a sex-interaction association at a protective
PICALM variant.74 This ﬁnding is consistent with what we observed,
as we saw a negative association with resilience at a PICALM risk
variant in males but a positive association in females. It is also noteworthy that PICALM contributes to multiple mechanisms involved
in the Alzheimer’s disease neuropathological cascade, including
neuroimmune processes.74 Taken together, this evidence may suggest that subtle sex differences at Alzheimer’s disease genetic loci
may contribute to sex differences in the downstream response to
Alzheimer’s disease pathology.

APOE effects not observed in resilient females
It was notable that we did not observe any statistically signiﬁcant
APOE × sex effects with resilience in our sensitivity
analyses (Supplementary Table 13). Multiple groups have shown
differential APOE effects by sex in females.12,75–78 As highlighted
in our original manuscript, accounting for cognitive variance related to amyloid appears to massively reduce the APOE signal,
and thus the reduced effect of APOE may partially explain the
lack of APOE-by-sex effects here. Additionally, our cohort is on
average older (mean age = 77) when the effects of APOE on cognition
are attenuated,8,9 and the effects of circulating oestrogens (that
have been hypothesized to modify APOE effects) are dramatically
reduced.

Comparison of study ﬁndings across resilience
phenotypes
Although signiﬁcant variant associations and genetic covariances
between residual cognitive resilience and combined resilience differed, the pattern of results was largely shared across resilience
phenotypes. For example, the female chromosome 10 resilience locus that was genome-wide signiﬁcant for combined resilience (with
rs827389) fell just below genome-wide signiﬁcant for residual cognitive resilience. In addition. the HRV genetic covariance ﬁndings
in males and the multiple sclerosis genetic covariance ﬁnding in females in the combined resilience phenotype also held true in the

Our study had multiple strengths. We harmonized data across four
deeply characterized cohorts of cognitive ageing, leveraged wellvalidated measures of amyloid, and implemented sex-aware statistical genetic analysis pipelines to identify sex-speciﬁc effects.
Moreover, our variant, gene, pathway, and cross-trait analyses provide novel insight into the shared genetic architecture between
cognitive resilience and other complex traits. However, our study
also had limitations. We were underpowered to detect genomewide sex-interaction effects. While we did not detect
X-chromosome variant-level sex effects and we did not investigate
imprinting, epigenetic or transcriptomic X-chromosome effects, we
are excited for future projects to dive into X-chromosome biology in
greater depth. Our study did not include measures of tau or other
known age-related neuropathologies. In addition, we did not include measures of neurodegeneration. We were additionally limited in the cognitive domains included in our cognitive resilience
models, including investigation of sub-domain effects. Finally,
our study was limited to non-Hispanic white individuals, and there
was limited heterogeneity in educational attainment, both attenuating the generalizability to other populations.

Conclusions
The ﬁndings of our sex-aware genetic study identiﬁed a locus, candidate genes, and molecular pathways that relate to resilience to
the cognitive consequences of the Alzheimer’s disease neuropathological cascade in a sex-speciﬁc manner. Our ﬁndings suggest
that the best target to enhance cognitive resilience to Alzheimer’s
disease pathology may depend on both the biological sex and the
genetic context of an individual.
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